UAMS Principal Investigator: Sukanthi Kovvuru, M.D., assistant professor, College of Medicine Department of Neurology
Summary: The HEALY ALS Platform Trial is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of multiple investigational products for the treatment of Amyotrophic Lateral Sclerosis (ALS). UAMS will begin with Regimen E – SLS-005 Trehalose and a matching placebo.
Significance: Researchers hope that the trial can identify a safe drug that will slow ALS’ rate of progression and/or improve ALS symptoms.
TRI Services: Medicare coverage analysis, study budget development, regulatory management, clinical/nurse coordinator and finance support.
Sponsor/Clinical Coordinating Center: Merit Cudkowicz, M.D., Director, Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital